Weekly chemo for advanced leiomyosarcoma in older adults
Treatments studied
Part of Cancer clinical trials.
This trial tests whether weekly doxorubicin is effective and tolerable for people aged 65 and older with advanced or metastatic leiomyosarcoma. It may be a good option if you have not had this type of chemo before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 to 100 years old.
- You have advanced or metastatic leiomyosarcoma that can't be removed by surgery.
- You have had 0 to 4 prior treatments for sarcoma, but not doxorubicin or similar drugs.
- You are willing to have two tumor biopsies (one before starting treatment and one after the first cycle).
- You have a central line (like a port or PICC) placed for chemotherapy.
- You are in generally good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests a new drug, BOLD-100, combined with the chemotherapy doxorubicin, for people with advanced or metastatic soft tissue sarcomas that haven't been treated before. The goal is to see if this combination works better than standard treatment.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
This early-phase study tests a special way to deliver medicine directly to the lungs (called IVLP) for sarcoma that has spread to both lungs. It aims to control lung metastases while reducing side effects, and it uses a plan that often includes surgery or focused radiation around the procedure.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.